The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation

被引:46
作者
Aguilar, P. R. [1 ]
Carpenter, D. [2 ]
Ritter, J. [3 ]
Yusen, R. D. [4 ]
Witt, C. A. [4 ]
Byers, D. E. [4 ]
Mohanakumar, T. [5 ]
Kreisel, D. [6 ]
Trulock, E. P. [4 ]
Hachem, R. R. [4 ]
机构
[1] Baylor Univ, Med Ctr, Div Pulm & Crit Care, Dallas, TX USA
[2] St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA
[3] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA
[4] Washington Univ, Div Pulm & Crit Care, Sch Med, St Louis, MO 63130 USA
[5] Norton Thorac Inst, Phoenix, AZ USA
[6] Washington Univ, Sch Med, Div Cardiothorac Surg, St Louis, MO 63110 USA
关键词
alloantibody; clinical research; practice; lung disease: immune; inflammatory; lung transplantation; pulmonology; rejection: antibody-mediated (ABMR); DONOR-SPECIFIC ANTIBODIES; ACUTE CELLULAR REJECTION; ALLOGRAFT-REJECTION; KIDNEY-TRANSPLANTATION; INTERNATIONAL SOCIETY; HEART-TRANSPLANTATION; DOUBLE-BLIND; BIOPSIES; OUTCOMES; ECULIZUMAB;
D O I
10.1111/ajt.14534
中图分类号
R61 [外科手术学];
学科分类号
摘要
Antibody-mediated rejection (AMR) is an increasingly recognized form of lung rejection. C4d deposition has been an inconsistent finding in previous reports and its role in the diagnosis has been controversial. We conducted a retrospective single-center study to characterize cases of C4d-negative probable AMR and to compare these to cases of definite (C4d-positive) AMR. We identified 73 cases of AMR: 28 (38%) were C4d-positive and 45 (62%) were C4d-negative. The two groups had a similar clinical presentation, and although more patients in the C4d-positive group had neutrophilic capillaritis (54% vs. 29%, P=.035), there was no significant difference in the presence of other histologic findings. Despite aggressive antibody-depleting therapy, 19 of 73 (26%) patients in the overall cohort died within 30days, but there was no significant difference in freedom from chronic lung allograft dysfunction (CLAD) or survival between the two groups. We conclude that AMR may cause allograft failure, but that the diagnosis requires a multidisciplinary approach and a high index of suspicion. C4d deposition does not appear to be a necessary criterion for the diagnosis, and although some cases may respond initially to therapy, there is a high incidence of CLAD and poor survival after AMR. In this retrospective single-center study, complement component 4d deposition does not appear to be a necessary criterion for the diagnosis of antibody-mediated rejection after lung transplantation.
引用
收藏
页码:936 / 944
页数:9
相关论文
共 36 条
[1]   Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT [J].
Berry, Gerald ;
Burke, Margaret ;
Andersen, Claus ;
Angelini, Annalisa ;
Bruneval, Patrick ;
Calbrese, Fiorella ;
Fishbein, Michael C. ;
Goddard, Martin ;
Leone, Ornella ;
Maleszewski, Joseph ;
Marboe, Charles ;
Miller, Dylan ;
Neil, Desley ;
Padera, Robert ;
Rassi, Doris ;
Revell, Monica ;
Rice, Alexandra ;
Stewart, Susan ;
Yousem, Samuel A. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2013, 32 (01) :14-21
[2]   Report of the Inefficacy of Eculizumab in Two Cases of Severe Antibody-Mediated Rejection of Renal Grafts [J].
Burbach, Maren ;
Suberbielle, Caroline ;
Brocheriou, Isabelle ;
Ridel, Christophe ;
Mesnard, Laurent ;
Dahan, Karine ;
Rondeau, Eric ;
Hertig, Alexandre .
TRANSPLANTATION, 2014, 98 (10) :1056-1059
[3]   Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure [J].
Campos, E. F. ;
Tedesco-Silva, H. ;
Machado, P. G. ;
Franco, M. ;
Medina-Pestana, J. O. ;
Gerbase-DeLima, M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (10) :2316-2320
[4]   Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation [J].
Clerkin, Kevin J. ;
Farr, Maryjane A. ;
Restaino, Susan W. ;
Zorn, Emmanuel ;
Latif, Farhana ;
Vasilescu, Elena R. ;
Marboe, Charles C. ;
Colombo, Paolo C. ;
Mancini, Donna M. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (05) :540-545
[5]   Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs [J].
Cross, Amy R. ;
Lion, Julien ;
Loiseau, Pascale ;
Charron, Dominique ;
Taupin, Jean-Luc ;
Glotz, Denis ;
Mooney, Nuala .
HUMAN IMMUNOLOGY, 2016, 77 (11) :1092-1100
[6]   A comparison of the antigen-presenting capabilities of class II MHC-expressing human lung epithelial and endothelial cells [J].
Cunningham, AC ;
Zhang, JG ;
Moy, JV ;
Ali, S ;
Kirby, JA .
IMMUNOLOGY, 1997, 91 (03) :458-463
[7]   Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab [J].
Dawson, Kyle L. ;
Parulekar, Amit ;
Seethamraju, Harish .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (12) :1325-1326
[8]   Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation [J].
DeVos, Jennifer M. ;
Gaber, A. Osama ;
Knight, Richard J. ;
Land, Geoffrey A. ;
Suki, Wadi N. ;
Gaber, Lillian W. ;
Patel, Samir J. .
KIDNEY INTERNATIONAL, 2012, 82 (05) :598-604
[9]   Proteasome Inhibitor Carfilzomib-Based Therapy for Antibody-Mediated Rejection of the Pulmonary Allograft: Use and Short-Term Findings [J].
Ensor, C. R. ;
Yousem, S. A. ;
Marrari, M. ;
Morrell, M. R. ;
Mangiola, M. ;
Pilewski, J. M. ;
D'Cunha, J. ;
Wisniewski, S. R. ;
Venkataramanan, R. ;
Zeevi, A. ;
McDyer, J. F. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (05) :1380-1388
[10]   Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions [J].
Haas, M. ;
Sis, B. ;
Racusen, L. C. ;
Solez, K. ;
Glotz, D. ;
Colvin, R. B. ;
Castro, M. C. R. ;
David, D. S. R. ;
David-Neto, E. ;
Bagnasco, S. M. ;
Cendales, L. C. ;
Cornell, L. D. ;
Demetris, A. J. ;
Drachenberg, C. B. ;
Farver, C. F. ;
Farris, A. B., III ;
Gibson, I. W. ;
Kraus, E. ;
Liapis, H. ;
Loupy, A. ;
Nickeleit, V. ;
Randhawa, P. ;
Rodriguez, E. R. ;
Rush, D. ;
Smith, R. N. ;
Tan, C. D. ;
Wallace, W. D. ;
Mengel, M. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (02) :272-283